SCHEMBL6715664

SCHEMBL6715664

COc1ccc(NC(=S)NC(C(=O)Nc2ccccc2C)c2ccccc2)c([N+](=O)[O-])c1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 10/20 0.56
KMT2A Q03164 10/20 0.56
ALDH1A1 P00352 13/20 0.55
MAPT P10636 11/20 0.55
TP53 P04637 2/20 0.55
RAB9A P51151 5/20 0.54
SMN1; SMN2 Q16637 4/20 0.54
NPC1 O15118 4/20 0.54
MAPK1 P28482 1/20 0.54
NPSR1 Q6W5P4 6/20 0.54
TDP1 Q9NUW8 3/20 0.54
POLB P06746 2/20 0.54
OPRK1 P41145 1/20 0.54
HTT P42858 5/20 0.52
LMNA P02545 4/20 0.51
NPY1R P25929 1/20 0.51
AKR1C3 P42330 1/20 0.50
AKR1C2 P52895 1/20 0.50
ALOX12 P18054 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8347861 1.00 MEN1 (0.56) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6716886 0.93 MAPT (0.58) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6719450 0.92 MAPT (0.57) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6715692 0.92 MEN1 (0.55) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6716665 0.91 SMN1; SMN2 (0.56) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6715739 0.91 MEN1 (0.56) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6714416 0.90 ALDH1A1 (0.62) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6723442 0.90 MEN1 (0.58) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL6715749 0.89 MEN1 (0.56) MEN1KMT2AALDH1A1MAPTTP53
SCHEMBL8345935 0.89 MEN1 (0.59) MEN1KMT2AALDH1A1MAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US claimed
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 MEN1 2933/4885KMT2A 2020/4885ALDH1A1 572/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.